The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

How do you like your Christmas lights? We all have our preferences, and we’re spoiled for choice, making it easy to decorate our trees exactly the way we want. You can pick white lights, multi-color ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Saddle systems improve every year. What once seemed like a niche piece of gear that lived in the periphery of more mainstream whitetail hunting alternatives, saddle hunting is the beneficiary of the ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Abstract: Cell-free massive multiple-input multiple-output (MIMO) is an attractive network in 6G communications that significantly increases the spectral efficiency. Operating in time-division duplex ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...